Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks

Molecular Cancer Research

Volumn 6, Issue 10, 2008, Pages 1621-1629

  Liu, Xuesong ^a   Shi, Yan ^a   Guan, Ran ^a   Donawho, Cherrie ^a   Luo, Yanping ^a   Palma, Joann ^a   Zhu, Gui Dong ^a   Johnson, Eric F ^a   Rodriguez, Luis E ^a   Ghoreishi Haack, Nayereh ^a   Jarvis, Ken ^a   Hradil, Vincent P ^a   Colon Lopez, Milagros ^a   Cox, Bryan F ^a   Klinghofer, Vered ^a   Penning, Thomas ^a   Rosenberg, Saul H ^a   Frost, David ^a   Giranda, Vincent L ^a   Luo, Yan ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 888; GADOLINIUM PENTETATE; HISTONE H2AX; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE S PHASE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DNA BINDING; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DNA STRAND BREAKAGE; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG SENSITIVITY; FEMALE; GLIOMA; HUMAN; HUMAN CELL; MELANOMA; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; CELL DEATH; CELL LINE, TUMOR; DACARBAZINE; DISEASE MODELS, ANIMAL; DNA BREAKS, DOUBLE-STRANDED; DNA BREAKS, SINGLE-STRANDED; DNA REPAIR; DNA REPLICATION; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HUMANS; MICE; POLY(ADP-RIBOSE) POLYMERASES; RATS;

ANIMALIA;

EID: 54249167431     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-08-0240     Document Type: Article

References (48)

1. Chambon P, Weill JD, Mandel JL. Nicotinamede mononucleotide activation of a new DNA-dependent poly-adenylic acid synthesizing enzyme. Biochem Biophys Res Commun 1963;11:39-43.
2. Amé Jean C, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays 2004;26:882-93.
3. Tulin A, Spradling A. Chromatin loosening by poly(ADP)-ribose polymerase (PARP) at Drosophila puff loci. Science 2003;299:560-2.
4. Kraus WL, Lis John T. PARP goes transcription. Cell 2003;113:677-83.
5. Tentori L, Portarena I, Graziani G. Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors. Pharmacol Res 2002;45:73-85.
6. Ménissier de Murcia J, Niedergang C, Trucco C, et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci U S A 1997;94:7303-7.
7. Schreiber V, Amé Jean C, Dollé P, et al. Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J Biol Chem 2002;277:23028-36.
8. Ménissier de Murcia J, Ricoul M, Tartier L, et al. Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse. EMBO J 2003;22:2255-63.
9. Virág L, Szabó C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 2002;54:375-429.
10. Pleschke JM, Kleczkowska HE, Strohm M, Althaus FR. Poly(ADP-ribose) binds to specific domains in DNA damage checkpoint proteins. J Biol Chem 2000;275:40974-80.
11. Curtin NJ, Wang L-Z, Yiakouvaki A, et al. Novel poly(ADP-ribose) polymerase-1 inhibitor, AG-14361, restores sensitivity to temozolomide in mismatch repair-deficient cells. Clin Cancer Res 2004;10:881-9.
12. Liu L, Taverna P, Whiteacre CM, Chatterjee S, Gerson SL. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and proficient colon cancer cells to methylating agents. Clin Cancer Res 1999;5:2908-17.
13. Cheng CL, Johnson Stewart P, Keir Stephen T, et al. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Molecular cancer therapeutics. Mol Cancer Ther 2005;4:1364-8.
14. Bryant HE, Helleday T. Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair. Nucleic Acids Res 2006;34:1685-91.
15. Hochegger H, Dejsuphong D, Fukushima T, et al. Parp-1 protects homologous recombination from interference by Ku and Ligase IV in vertebrate cells. EMBO J 2006;25:1305-14.
16. Wang M, Wu W, Wu W, et al. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res 2006;34:6170-82.
17. Tomoda T, Kurashige T, Moriki T, Yamamoto H, Fujimoto S, Taniguchi T. Enhanced expression of poly(ADP-ribose) synthetase gene in malignant lymphoma. Am J Hematol 1991;37:223-7.
18. Wielckens K, Garbrecht M, Kittler M, Hilz H. ADP-ribosylation of nuclear proteins in normal lymphocytes and in low- grade malignant non-Hodgkin lymphoma cells. Eur J Biochem 1980;104:279-87.
19. Nomura F, Yaguchi M, Togawa A, et al. Enhancement of poly-adenosine diphosphate-ribosylation in human hepatocellular carcinoma. J Gastroenterol Hepatol 2000;15:529-35.
20. Shiobara M, Miyazaki M, Ito H, et al. Enhanced polyadenosine diphosphateribosylation in cirrhotic liver and carcinoma tissues in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2001;16:338-44.
21. Kubo S, Matsutani M, Nakagawa K, Ogura T, Esumi H, Saijo N. Participation of poly(ADP-ribose) polymerase in the drug sensitivity in human lung cancer cell lines. J Cancer Res Clin Oncol 1992;118:244-8.
22. Fukushima M, Kuzuya K, Ota K, Ikai K. Poly(ADP-ribose) synthesis in human cervical cancer cell-diagnostic cytological usefulness. Cancer Lett 1981;14:227-36.
23. McNealy T, Frey M, Trojon L, Knoll T, Alken P, Michel Maurice S. Intrinsic presence of poly (ADP-ribose) is significantly increased in malignant prostate compared to benign prostate cell lines. Anticancer Res 2003;23:1473-8.
24. Curtin NJ, Wang LZ, Yiakouvaki A, et al. Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells. Clin Cancer Res 2004;10:881-9.
25. Delaney CA, Wang LZ, Kyle S, et al. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res 2000;6:2860-7.
26. Miknyoczki SJ, Jones Bolin S, Pritchard S, et al. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther 2003;2:371-82.
27. Tentori L, Leonetti C, Scarsella M, et al. Systemic administration of the PARP inhibitor GPI 15427 increases the anti-tumor activity of temozolomide in melanoma, glioma and lymphoma preclinical models in vivo. Proc Am Assoc Cancer Res Annu Meet 2003;44:1088-9.
28. Tentori L, Leonetti C, Scarsella M, et al. Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood 2002;99:2241-4.
29. Tentori L, Leonetti C, Scarsella M, et al. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res 2003;9:5370-9.
30. Calabrese CR, Almassy R, Barton S, et al. Anticancer chemosensitization and radiosensitization by the novel poly (ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 2004;96:56-67.
31. Calabrese CR, Batey MA, Thomas HD, et al. Identification of potent nontoxic poly(ADP-ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin Cancer Res 2003;9:2711-8.
32. Veuger SJ, Curtin NJ, Richardson CJ, Smith GCM, Durkacz BW. Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. Cancer Res 2003;63:6008-15.
33. D'Atri S, Tentori L, Lacal PM, et al. Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol 1998;54:334-41.
34. 6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. Clin Cancer Res 2005;11:3402-9.
35. Taneja N, Davis M, Choy JS, et al. Histone H2AX phosphorylation as a predictor of radiosensitivity and target for radiotherapy. J Biol Chem 2004;279:2273-80.
36. Olive PL, Banáth JP, Sinnott LT. Phosphorylated histone H2AX in spheroids, tumors, and tissues of mice exposed to etoposide and 3-amino-1,2,4-benzotriazine-1,3-dioxide. Cancer Res 2004;64:5363-9.
37. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003;421:499-506.
38. Burma S, Chen BP, Murphy M, Kurimasa A, Chen DJ. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem 2001;276:42462-7.
39. Lukas C, Melander F, Stucki M, et al. Mdc1 couples DNA double-strand break recognition by Nbs1 with its H2AX-dependent chromatin retention. EMBO J 2004;23:2674-83.
40. Paull TT, Rogakou EP, Yamazaki V, Kirchgessner CU, Gellert M, Bonner WM. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol 2000;10:886-95.
41. Ward IM, Chen J. Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress. J Biol Chem 2001;276:47759-62.
42. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998;273:5858-68.
43. Stiff T, Mark OD, Rief N, Iwabuchi K, Löbrich M, Jeggo PA. ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation. Cancer Res 2004;64:2390-6.
44. Donawho CK, Luo Y, Luo Y, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007;13:2728-37.
45. Dianov GL, KM SD II, Allison SL. Repair of abasic sites in DNA. Mutat Res 2003;531:157-63.
46. Masson M, Niedergang C, Schreiber V, Muller S, Menissier de Murcia J, de Murcia G. XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol 1998;18:3563-71.
47. Albert JM, Cao CX, Kim KW, et al. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res 2007;13:3033-42.
48. Liu X, Shi Y, Han EK, et al. Downregulation of Akt1 inhibits anchorage-independent cell growth and induces apoptosis in cancer cells. Neoplasia 2001;3:278-86.